Celldex Therapeutics' Varlilumab Continues to Demonstrate Very Favorable Profile | Melanoma Dispatch | Scoop.it

"Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported data from its ongoing Phase 1 study of the fully human monoclonal antibody varlilumab (CDX-1127) in cancer. Varlilumab is an immunotherapy designed to enhance the body's natural immune response by directly activating T cells that can specifically recognize and kill cancer cells. Preclinical data support the broad study of varlilumab in combination with a number of other anti-cancer agents including but not limited to checkpoint inhibitors, chemotherapies, targeted therapies and vaccines. Varlilumab will enter at least four combination studies in the second half of 2014."

Editor's note: As mentioned above, varlilumab is an immunotherapy that works by boosting a patient's own immune system to fight cancer. In a clinical trial testing the drug in volunteer patients, it shown promise for treating several different types of cancer, including metastatic melanoma.